Search

Your search keyword '"Suman, Vera J"' showing total 781 results
Start Over Author "Suman, Vera J"
781 results on '"Suman, Vera J"'

1. Pre-treatment peripheral blood immunophenotyping and response to neoadjuvant chemotherapy in operable breast cancer

Author

Leon-Ferre, Roberto A., Whitaker, Kaitlyn R., Suman, Vera J., Hoskin, Tanya, Giridhar, Karthik V., Moore, Raymond M., Al-Jarrad, Ahmad, McLaughlin, Sarah A., Northfelt, Donald W., Hunt, Katie N., Conners, Amy Lynn, Moyer, Ann, Carter, Jodi M., Kalari, Krishna, Weinshilboum, Richard, Wang, Liewei, Ingle, James N., Knutson, Keith L., Ansell, Stephen M., Boughey, Judy C., Goetz, Matthew P., and Villasboas, Jose C.

Published
2024
Full Text
View/download PDF

3. Neoadjuvant cobimetinib and atezolizumab with or without vemurafenib for high-risk operable Stage III melanoma: the Phase II NeoACTIVATE trial

Author

Hieken, Tina J., Nelson, Garth D., Flotte, Thomas J., Grewal, Eric P., Chen, Jun, McWilliams, Robert R., Kottschade, Lisa A., Yang, Lu, Domingo-Musibay, Evidio, Dronca, Roxana S., Yan, Yiyi, Markovic, Svetomir N., Dimou, Anastasios, Montane, Heather N., Erskine, Courtney L., Piltin, Mara A., Price, Daniel L., Khariwala, Samir S., Hui, Jane, Strand, Carrie A., Harrington, Susan M., Suman, Vera J., Dong, Haidong, and Block, Matthew S.

Published
2024
Full Text
View/download PDF

7. Anthracycline-containing and taxane-containing chemotherapy for early-stage operable breast cancer: a patient-level meta-analysis of 100 000 women from 86 randomised trials

Author

Braybrooke, Jeremy, Bradley, Rosie, Gray, Richard, Hills, Robert K, Pan, Hongchao, Peto, Richard, Dodwell, David, McGale, Paul, Taylor, Carolyn, Aihara, Tomohiko, Anderson, Stewart, Blum, Joanne, Cardoso, Fatima, Chen, Xiaosong, Crown, John P, Ejlertsen, Bent, Friedl, Thomas W P, Harbeck, Nadia, Janni, Wolfgang, Jensen, Maj-Britt, Mamounas, Eleftherios, Narui, Kazutaka, Nitz, Ulrike, Norton, Larry, O'Shaughnessy, Joyce, Piccart, Martine, Robert, Nicholas, Shao, Zhi-Ming, Slamon, Dennis, Sparano, Joseph, Watanabe, Toru, Yothers, Greg, Yu, Ke-Da, Berry, Richard, Boddington, Clare, Clarke, Mike, Davies, Christina, Davies, Lucy, Duane, Fran, Evans, Vaughan, Gay, Jo, Gettins, Lucy, Godwin, Jon, James, Sam, Lui, Hui, Lui, Zulian, MacKinnon, Elizabeth, Mannu, Gurdeep, McHugh, Theresa, Morris, Philip, Read, Simon, Straiton, Ewan, Buzdar, Aman, Suman, Vera J, Hunt, Kelly K, Leonard, Robert C F, Mansi, Janine, Delbaldo, Catherine, Piedbois, Pascal, Quinaux, Emmanuel, Fesl, Christian, Gnant, Michael, Sölkner, Lidija, Steger, Guenther, Eikesdal, Hans Petter, Lønning, Per Eystein, Bee, Valerie, Fung, Helena, Mackey, John, Martin, Miguel, Press, Michael, De Azambuja, Evandro, Gelber, Richard, Regan, Meredith, Di Leo, Angelo, Van Dooren, Veerle, Nogaret, Jean Marie, Bartlett, John, Chen, Bingshu E, Gelmon, Karen, Goss, Paul E, Levine, Mark N, Parulekar, Wendy, Pritchard, Kathleen I, Shepherd, Lois, Berry, Donald, Cirrincione, Constance, Shulman, Lawrence N, Winer, Eric, Gelman, Rebecca S, Harris, Jay R, Henderson, Craig, Shapiro, Charles L, Christiansen, Peer, Ewertz, Marianne, Mouridsen, Henning T, Van Leeuwen, Elise, Linn, Sabine, Van Rossum, Annelot G J, Van Tinteren, Harm, Van Werkhoven, Erik, Goldstein, Lori, Gray, Robert, Eiermann, Wolfgang, Gianni, Luca, Valagussa, Pinuccia, Bogaerts, Jan, Bonnefoi, Herve, Poncet, Coralie, Huovinen, Riikka, Joensuu, Heikki, Bonneterre, Jacques, Fargeot, Pierre, Fumoleau, Pierre, Kerbrat, Pierre, Luporsi, Elisabeth, Namer, Moïse, Carrasco, Eva M, Segui, Miguel Angel, Meisner, Christoph, Loibl, Sibylle, Nekljudova, Valentina, Thomssen, Christoph, Von Minckwitz, Gunter, Kümmel, Sherko, Lopez, Massimo, Vici, Patrizia, Fountzilas, George, Koliou, Georgia, Mavroudis, Dimitrios, Saloustros, Emmanouil, Brain, Etienne, Delaloge, Suzette, Michiels, Stefan, Mathoulin-Pelissier, Simone, Bines, Jose, Sarmento, Roberta M B, Bonadonna, Gianni, Brambilla, Cristina, Rossi, Anna, Bliss, Judith, Coombes, Raoul Charles, Kilburn, Lucy, Marty, Michel, Amadori, Dino, Boccardo, Francesco, Nanni, Oriana, Rubagotti, Alessandra, Scarpi, Emanuela, Masuda, Norikazu, Toi, Masakazu, Ueno, Takayuki, Ishikawa, Takashi, Matsumoto, Koji, Takao, Shintaro, Sommer, Harald, Foroglou, Pericles, Giokas, George, Kondylis, D, Lissaios, Byron, Reinisch, Mattea, Lee, Keun Seok, Nam, Byung-Ho, Ro, Jung Sil, De Matteis, Andrea, Perrone, Francesco, Tang, Gong, Wolmark, Norman, Hozumi, Yasuo, Nomura, Yasuo, Earl, Helena, Hiller, Louise, Vallier, Anne-Laure, De Mastro, Lucia, Venturini, Macro, Delozier, Thierry, Lemonnier, Jerome, Martin, Anne-Laure, Roché, Henri, Spielmann, Marc, Chen, Xiasong, Shen, Kunwei, Albain, Kathy, Barlow, William, Budd, George T, Gralow, Julie, Hayes, Dan, Bartlett-Lee, Peter, Ellis, Paul, Bianco, Angelo Raffaele, De Laurentiis, Michelino, De Placido, Sabino, Wildiers, Hans, Hsu, Limin, Eremin, Oleg, Walker, Leslie G, Ahlgren, Johan, Blomqvist, Carl, Holmberg, Lars, Lindman, Henrik, Asmar, Lina, Jones, Stephen E, Gluz, Oleg, Liedtke, Cornelia, Arriagada, Rodrigo, Bergsten-Nordström, Elizabeth, Carey, Lisa, Coleman, Robert, Cuzick, Jack, Davidson, Nancy, Dignam, James, Dowsett, Mitch, Francis, Prudence A, Goetz, Matthew P, Goodwin, Pam, Halpin-Murphy, Pat, Hill, Catherine, Jagsi, Reshma, Mukai, Hirofumi, Ohashi, Yasuo, Pierce, Lori, Poortmans, Philip, Raina, Vinod, Rea, Daniel, Robertson, John, Rutgers, Emiel, Salgado, Roberto, Spanic, Tanja, Tutt, Andrew, Viale, Giuseppe, Wang, Xiang, Whelan, Tim, Wilcken, Nicholas, Cameron, David, Bergh, Jonas, and Swain, Sandra M

Published
2023
Full Text
View/download PDF

8. Estrogen receptor beta repurposes EZH2 to suppress oncogenic NFκB/p65 signaling in triple negative breast cancer

Author

Aspros, Kirsten G. M., Carter, Jodi M., Hoskin, Tanya L., Suman, Vera J., Subramaniam, Malayannan, Emch, Michael J., Ye, Zhenqing, Sun, Zhifu, Sinnwell, Jason P., Thompson, Kevin J., Tang, Xiaojia, Rodman, Esther P. B., Wang, Xiyin, Nelson, Adam W., Chernukhin, Igor, Hamdan, Feda H., Bruinsma, Elizabeth S., Carroll, Jason S., Fernandez-Zapico, Martin E., Johnsen, Steven A., Kalari, Krishna R., Huang, Haojie, Leon-Ferre, Roberto A., Couch, Fergus J., Ingle, James N., Goetz, Matthew P., and Hawse, John R.

Published
2022
Full Text
View/download PDF

9. ASO Visual Abstract: Local-Regional Recurrence Following Neoadjuvant Endocrine Therapy – Data from ACOSOG Z1031 (Alliance), a Randomized Phase II Neoadjuvant Comparison Between Letrozole, Anastrozole, and Exemestane for Postmenopausal Women with Estrogen Receptor–Positive Clinical Stage 2–3 Breast Cancer

Author

Hunt, Kelly K., Suman, Vera J., Wingate, Hannah F., Leitch, A. Marilyn, Unzeitig, Gary, Boughey, Judy C., Meric-Bernstam, Funda, Ellis, Matthew J., and Olson, John A.

Published
2023
Full Text
View/download PDF

10. A Phase I trial of Nab-Paclitaxel/Bevacizumab (AB160) Nano-Immunoconjugate Therapy for Gynecologic Malignancies

Author

Kalogera, Eleftheria, primary, Nevala, Wendy K., additional, Finnes, Heidi D., additional, Suman, Vera J., additional, Schimke, Jill M., additional, Strand, Carrie A., additional, Kottschade, Lisa A., additional, Kudgus, Rachel A., additional, Buhrow, Sarah A., additional, Becher, Laura R., additional, Geng, Liyi, additional, Glaser, Gretchen E., additional, Grudem, Megan E., additional, Jatoi, Aminah, additional, Klampe, Carolyn M., additional, Kumar, Amanika, additional, Langstraat, Carrie L., additional, McWilliams, Robert R., additional, Wahner Hendrickson, Andrea E., additional, Weroha, S. John, additional, Yan, Yiyi, additional, Reid, Joel M., additional, Markovic, Svetomir N., additional, and Block, Matthew S., additional

Published
2024
Full Text
View/download PDF

11. Endocrine-Sensitive Disease Rate in Postmenopausal Patients With Estrogen Receptor–Rich/ERBB2-Negative Breast Cancer Receiving Neoadjuvant Anastrozole, Fulvestrant, or Their Combination

Author

Ma, Cynthia X., primary, Suman, Vera J., additional, Sanati, Souzan, additional, Vij, Kiran, additional, Anurag, Meenakshi, additional, Leitch, A. Marilyn, additional, Unzeitig, Gary W., additional, Hoog, Jeremy, additional, Fernandez-Martinez, Aranzazu, additional, Fan, Cheng, additional, Gibbs, Richard A., additional, Watson, Mark A., additional, Dockter, Travis J., additional, Hahn, Olwen, additional, Guenther, Joseph M., additional, Caudle, Abigail, additional, Crouch, Erika, additional, Tiersten, Amy, additional, Mita, Monica, additional, Razaq, Wajeeha, additional, Hieken, Tina J., additional, Wang, Yang, additional, Rimawi, Mothaffar F., additional, Weiss, Anna, additional, Winer, Eric P., additional, Hunt, Kelly K., additional, Perou, Charles M., additional, Ellis, Matthew J., additional, Partridge, Ann H., additional, and Carey, Lisa A., additional

Published
2024
Full Text
View/download PDF

12. Ki67 Proliferation Index as a Tool for Chemotherapy Decisions During and After Neoadjuvant Aromatase Inhibitor Treatment of Breast Cancer: Results From the American College of Surgeons Oncology Group Z1031 Trial (Alliance)

Author

Ellis, Matthew J, Suman, Vera J, Hoog, Jeremy, Goncalves, Rodrigo, Sanati, Souzan, Creighton, Chad J, DeSchryver, Katherine, Crouch, Erika, Brink, Amy, Watson, Mark, Luo, Jingqin, Tao, Yu, Barnes, Michael, Dowsett, Mitchell, Budd, G Thomas, Winer, Eric, Silverman, Paula, Esserman, Laura, Carey, Lisa, X., Cynthia, Unzeitig, Gary, Pluard, Timothy, Whitworth, Pat, Babiera, Gildy, Guenther, J Michael, Dayao, Zoneddy, Ota, David, Leitch, Marilyn, Olson, John A, Allred, D Craig, and Hunt, Kelly

Subjects
Cancer, Aging, Estrogen, Clinical Trials and Supportive Activities, Clinical Research, Breast Cancer, Development of treatments and therapeutic interventions, Evaluation of treatments and therapeutic interventions, 6.1 Pharmaceuticals, 5.1 Pharmaceuticals, 4.2 Evaluation of markers and technologies, Detection, screening and diagnosis, Aged, Anastrozole, Androstadienes, Antineoplastic Combined Chemotherapy Protocols, Aromatase Inhibitors, Breast Neoplasms, Clinical Decision-Making, Female, Follow-Up Studies, Humans, Ki-67 Antigen, Letrozole, Middle Aged, Mitotic Index, Neoadjuvant Therapy, Neoplasm Metastasis, Neoplasm Recurrence, Local, Neoplasm Staging, Nitriles, Predictive Value of Tests, Prognosis, Proportional Hazards Models, Receptors, Estrogen, Receptors, Progesterone, Survival Rate, Transcriptome, Triazoles, Clinical Sciences, Oncology and Carcinogenesis, Oncology & Carcinogenesis
Abstract

Purpose To determine the pathologic complete response (pCR) rate in estrogen receptor (ER) -positive primary breast cancer triaged to chemotherapy when the protein encoded by the MKI67 gene (Ki67) level was > 10% after 2 to 4 weeks of neoadjuvant aromatase inhibitor (AI) therapy. A second objective was to examine risk of relapse using the Ki67-based Preoperative Endocrine Prognostic Index (PEPI). Methods The American College of Surgeons Oncology Group (ACOSOG) Z1031A trial enrolled postmenopausal women with stage II or III ER-positive (Allred score, 6 to 8) breast cancer whose treatment was randomly assigned to neoadjuvant AI therapy with anastrozole, exemestane, or letrozole. For the trial ACOSOG Z1031B, the protocol was amended to include a tumor Ki67 determination after 2 to 4 weeks of AI. If the Ki67 was > 10%, patients were switched to neoadjuvant chemotherapy. A pCR rate of > 20% was the predefined efficacy threshold. In patients who completed neoadjuvant AI, stratified Cox modeling was used to assess whether time to recurrence differed by PEPI = 0 score (T1 or T2, N0, Ki67 < 2.7%, ER Allred > 2) versus PEPI > 0 disease. Results Only two of the 35 patients in ACOSOG Z1031B who were switched to neoadjuvant chemotherapy experienced a pCR (5.7%; 95% CI, 0.7% to 19.1%). After 5.5 years of median follow-up, four (3.7%) of the 109 patients with a PEPI = 0 score relapsed versus 49 (14.4%) of 341 of patients with PEPI > 0 (recurrence hazard ratio [PEPI = 0 v PEPI > 0], 0.27; P = .014; 95% CI, 0.092 to 0.764). Conclusion Chemotherapy efficacy was lower than expected in ER-positive tumors exhibiting AI-resistant proliferation. The optimal therapy for these patients should be further investigated. For patients with PEPI = 0 disease, the relapse risk over 5 years was only 3.6% without chemotherapy, supporting the study of adjuvant endocrine monotherapy in this group. These Ki67 and PEPI triage approaches are being definitively studied in the ALTERNATE trial (Alternate Approaches for Clinical Stage II or III Estrogen Receptor Positive Breast Cancer Neoadjuvant Treatment in Postmenopausal Women: A Phase III Study; clinical trial information: NCT01953588).

Published
2017

13. Summary of the 2019 Blood and Marrow Transplant Clinical Trials Network Myeloma Intergroup Workshop on Minimal Residual Disease and Immune Profiling

Author

Holstein, Sarah A., Howard, Alan, Avigan, David, Bhutani, Manisha, Cohen, Adam D., Costa, Luciano J., Dhodapkar, Madhav V., Gay, Francesca, Gormley, Nicole, Green, Damian J., Hillengass, Jens, Korde, Neha, Li, Zihai, Mailankody, Sham, Neri, Paola, Parekh, Samir, Pasquini, Marcelo C., Puig, Noemi, Roodman, G. David, Samur, Mehmet Kemal, Shah, Nina, Shah, Urvi A., Shi, Qian, Spencer, Andrew, Suman, Vera J., Usmani, Saad Z., and McCarthy, Philip L.

Published
2020
Full Text
View/download PDF

15. Benign Breast Disease and the Risk of Breast Cancer

Author

Hartmann, Lynn C, Sellers, Thomas A, Frost, Marlene H, Lingle, Wilma L, Degnim, Amy C, Ghosh, Karthik, Vierkant, Robert A, Maloney, Shaun D, Pankratz, V Shane, Hillman, David W, Suman, Vera J, Johnson, Jo, Blake, Cassann, Tlsty, Thea, Vachon, Celine M, Melton, L Joseph, and Visscher, Daniel W

Subjects
Patient Safety, Clinical Research, Cancer, Breast Cancer, Paediatrics and Reproductive Medicine, Obstetrics & Reproductive Medicine
Published
2016

16. Correction to: Establishing and characterizing patient-derived xenografts using pre-chemotherapy percutaneous biopsy and post-chemotherapy surgical samples from a prospective neoadjuvant breast cancer study

Author

Yu, Jia, Qin, Bo, Moyer, Ann M., Sinnwell, Jason P., Thompson, Kevin J., Copland, III, John A., Marlow, Laura A., Miller, James L., Yin, Ping, Gao, Bowen, Minter-Dykhouse, Katherine, Tang, Xiaojia, McLaughlin, Sarah A., Moreno-Aspitia, Alvaro, Schweitzer, Anthony, Lu, Yan, Hubbard, Jason, Northfelt, Donald W., Gray, Richard J., Hunt, Katie, Conners, Amy L., Suman, Vera J., Kalari, Krishna R., Ingle, James N., Lou, Zhenkun, Visscher, Daniel W., Weinshilboum, Richard, Boughey, Judy C., Goetz, Matthew P., and Wang, Liewei

Published
2021
Full Text
View/download PDF

17. Tumor-Infiltrating Lymphocytes in Triple-Negative Breast Cancer.

Author

Leon-Ferre, Roberto A., Jonas, Sarah Flora, Salgado, Roberto, Loi, Sherene, de Jong, Vincent, Carter, Jodi M., Nielsen, Torsten O., Leung, Samuel, Riaz, Nazia, Chia, Stephen, Jules-Clément, Gérôme, Curigliano, Giuseppe, Criscitiello, Carmen, Cockenpot, Vincent, Lambertini, Matteo, Suman, Vera J., Linderholm, Barbro, Martens, John W. M., van Deurzen, Carolien H. M., and Timmermans, A. Mieke

Subjects
TRIPLE-negative breast cancer, TUMOR-infiltrating immune cells, CANCER relapse, RADIOTHERAPY, NEOADJUVANT chemotherapy, LIKELIHOOD ratio tests, PROGNOSIS
Abstract

Key Points: Question: In patients with early-stage triple-negative breast cancer (TNBC) treated with locoregional therapy but without adjuvant or neoadjuvant chemotherapy, is a higher abundance of tumor-infiltrating lymphocytes (TIL) in breast cancer tissue associated with better survival? Findings: In this retrospective analysis of 1966 participants with early-stage TNBC treated with locoregional therapy but without adjuvant or neoadjuvant chemotherapy, survival rates were 90% for patients with a TIL level of 50% or greater, compared with 72% for patients with a TIL level of less than 30% at 5-year follow-up. Meaning: In patients with early-stage TNBC treated with locoregional therapy only, higher TIL levels in breast cancer tissue were associated with improved survival. Importance: The association of tumor-infiltrating lymphocyte (TIL) abundance in breast cancer tissue with cancer recurrence and death in patients with early-stage triple-negative breast cancer (TNBC) who are not treated with adjuvant or neoadjuvant chemotherapy is unclear. Objective: To study the association of TIL abundance in breast cancer tissue with survival among patients with early-stage TNBC who were treated with locoregional therapy but no chemotherapy. Design, Setting, and Participants: Retrospective pooled analysis of individual patient-level data from 13 participating centers in North America (Rochester, Minnesota; Vancouver, British Columbia, Canada), Europe (Paris, Lyon, and Villejuif, France; Amsterdam and Rotterdam, the Netherlands; Milan, Padova, and Genova, Italy; Gothenburg, Sweden), and Asia (Tokyo, Japan; Seoul, Korea), including 1966 participants diagnosed with TNBC between 1979 and 2017 (with follow-up until September 27, 2021) who received treatment with surgery with or without radiotherapy but no adjuvant or neoadjuvant chemotherapy. Exposure: TIL abundance in breast tissue from resected primary tumors. Main Outcomes and Measures: The primary outcome was invasive disease-free survival [iDFS]. Secondary outcomes were recurrence-free survival [RFS], survival free of distant recurrence [distant RFS, DRFS], and overall survival. Associations were assessed using a multivariable Cox model stratified by participating center. Results: This study included 1966 patients with TNBC (median age, 56 years [IQR, 39-71]; 55% had stage I TNBC). The median TIL level was 15% (IQR, 5%-40%). Four-hundred seventeen (21%) had a TIL level of 50% or more (median age, 41 years [IQR, 36-63]), and 1300 (66%) had a TIL level of less than 30% (median age, 59 years [IQR, 41-72]). Five-year DRFS for stage I TNBC was 94% (95% CI, 91%-96%) for patients with a TIL level of 50% or more, compared with 78% (95% CI, 75%-80%) for those with a TIL level of less than 30%; 5-year overall survival was 95% (95% CI, 92%-97%) for patients with a TIL level of 50% or more, compared with 82% (95% CI, 79%-84%) for those with a TIL level of less than 30%. At a median follow-up of 18 years, and after adjusting for age, tumor size, nodal status, histological grade, and receipt of radiotherapy, each 10% higher TIL increment was associated independently with improved iDFS (hazard ratio [HR], 0.92 [0.89-0.94]), RFS (HR, 0.90 [0.87-0.92]), DRFS (HR, 0.87 [0.84-0.90]), and overall survival (0.88 [0.85-0.91]) (likelihood ratio test, P < 10e-6). Conclusions and Relevance: In patients with early-stage TNBC who did not undergo adjuvant or neoadjuvant chemotherapy, breast cancer tissue with a higher abundance of TIL levels was associated with significantly better survival. These results suggest that breast tissue TIL abundance is a prognostic factor for patients with early-stage TNBC. This study of patients with early-stage triple-negative breast cancer not treated with adjuvant or neoadjuvant chemotherapy analyzes the association between tumor-infiltrating lymphocyte levels, cancer recurrence, and survival. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

21. Whole-genome analysis informs breast cancer response to aromatase inhibition

Author

Ellis, Matthew J, Ding, Li, Shen, Dong, Luo, Jingqin, Suman, Vera J, Wallis, John W, Van Tine, Brian A, Hoog, Jeremy, Goiffon, Reece J, Goldstein, Theodore C, Ng, Sam, Lin, Li, Crowder, Robert, Snider, Jacqueline, Ballman, Karla, Weber, Jason, Chen, Ken, Koboldt, Daniel C, Kandoth, Cyriac, Schierding, William S, McMichael, Joshua F, Miller, Christopher A, Lu, Charles, Harris, Christopher C, McLellan, Michael D, Wendl, Michael C, DeSchryver, Katherine, Allred, D Craig, Esserman, Laura, Unzeitig, Gary, Margenthaler, Julie, Babiera, GV, Marcom, P Kelly, Guenther, JM, Leitch, Marilyn, Hunt, Kelly, Olson, John, Tao, Yu, Maher, Christopher A, Fulton, Lucinda L, Fulton, Robert S, Harrison, Michelle, Oberkfell, Ben, Du, Feiyu, Demeter, Ryan, Vickery, Tammi L, Elhammali, Adnan, Piwnica-Worms, Helen, McDonald, Sandra, Watson, Mark, Dooling, David J, Ota, David, Chang, Li-Wei, Bose, Ron, Ley, Timothy J, Piwnica-Worms, David, Stuart, Joshua M, Wilson, Richard K, and Mardis, Elaine R

Subjects
Biological Sciences, Biomedical and Clinical Sciences, Genetics, Clinical Sciences, Oncology and Carcinogenesis, Cancer, Breast Cancer, Human Genome, Biotechnology, Anastrozole, Androstadienes, Antineoplastic Agents, Aromatase, Aromatase Inhibitors, Breast Neoplasms, DNA Repair, Exome, Exons, Female, Genetic Variation, Genome, Human, Humans, Letrozole, MAP Kinase Kinase 4, MAP Kinase Kinase Kinase 1, Mutation, Nitriles, Receptors, Estrogen, Treatment Outcome, Triazoles, General Science & Technology
Abstract

To correlate the variable clinical features of oestrogen-receptor-positive breast cancer with somatic alterations, we studied pretreatment tumour biopsies accrued from patients in two studies of neoadjuvant aromatase inhibitor therapy by massively parallel sequencing and analysis. Eighteen significantly mutated genes were identified, including five genes (RUNX1, CBFB, MYH9, MLL3 and SF3B1) previously linked to haematopoietic disorders. Mutant MAP3K1 was associated with luminal A status, low-grade histology and low proliferation rates, whereas mutant TP53 was associated with the opposite pattern. Moreover, mutant GATA3 correlated with suppression of proliferation upon aromatase inhibitor treatment. Pathway analysis demonstrated that mutations in MAP2K4, a MAP3K1 substrate, produced similar perturbations as MAP3K1 loss. Distinct phenotypes in oestrogen-receptor-positive breast cancer are associated with specific patterns of somatic mutations that map into cellular pathways linked to tumour biology, but most recurrent mutations are relatively infrequent. Prospective clinical trials based on these findings will require comprehensive genome sequencing.

Published
2012

22. Evidence-based guidelines for managing patients with primary ER+ HER2− breast cancer deferred from surgery due to the COVID-19 pandemic

Author

Dowsett, Mitch, Ellis, Matthew J., Dixon, J. Michael, Gluz, Oleg, Robertson, John, Kates, Ronald, Suman, Vera J., Turnbull, Arran K., Nitz, Ulrike, Christgen, Matthias, Kreipe, Hans, Kuemmel, Sherko, Bliss, Judith M., Barry, Peter, Johnston, Stephen R., Jacobs, Samuel A., Ma, Cynthia X., Smith, Ian E., and Harbeck, Nadia

Published
2020
Full Text
View/download PDF

25. Benign Breast Disease and the Risk of Breast Cancer

Author

Hartmann, Lynn C, Sellers, Thomas A, Frost, Marlene H, Lingle, Wilma L, Degnim, Amy C, Ghosh, Karthik, Vierkant, Robert A, Maloney, Shaun D, Pankratz, V Shane, Hillman, David W, Suman, Vera J, Johnson, Jo, Blake, Cassann, Tlsty, Thea, Vachon, Celine M, Melton, L Joseph, and Visscher, Daniel W

Subjects
Cancer, Prevention, Clinical Research, Breast Cancer, Adult, Age of Onset, Aged, Breast, Breast Diseases, Breast Neoplasms, Cohort Studies, Female, Fibrocystic Breast Disease, Humans, Hyperplasia, Middle Aged, Proportional Hazards Models, Risk, Medical and Health Sciences, General & Internal Medicine
Abstract

BackgroundBenign breast disease is an important risk factor for breast cancer. We studied a large group of women with benign breast disease to obtain reliable estimates of this risk.MethodsWe identified all women who received a diagnosis of benign breast disease at the Mayo Clinic between 1967 and 1991. Breast-cancer events were obtained from medical records and questionnaires. To estimate relative risks, we compared the number of observed breast cancers with the number expected on the basis of the rates of breast cancer in the Iowa Surveillance, Epidemiology, and End Results registry.ResultsWe followed 9087 women for a median of 15 years. The histologic findings were nonproliferative lesions in 67 percent of women, proliferative lesions without atypia in 30 percent, and atypical hyperplasia in 4 percent. To date, 707 breast cancers have developed. The relative risk of breast cancer for the cohort was 1.56 (95 percent confidence interval, 1.45 to 1.68), and this increased risk persisted for at least 25 years after biopsy. The relative risk associated with atypia was 4.24 (95 percent confidence interval, 3.26 to 5.41), as compared with a relative risk of 1.88 (95 percent confidence interval, 1.66 to 2.12) for proliferative changes without atypia and of 1.27 (95 percent confidence interval, 1.15 to 1.41) for nonproliferative lesions. The strength of the family history of breast cancer, available for 4808 women, was a risk factor that was independent of histologic findings. No increased risk was found among women with no family history and nonproliferative findings. In the first 10 years after the initial biopsy, an excess of cancers occurred in the same breast, especially in women with atypia.ConclusionsRisk factors for breast cancer after the diagnosis of benign breast disease include the histologic classification of a benign breast lesion and a family history of breast cancer.

Published
2005

26. DNA methyltransferase expression in triple-negative breast cancer predicts sensitivity to decitabine

Author

Yu, Jia, Qin, Bo, Moyer, Ann M., Nowsheen, Somaira, Liu, Tongzheng, Qin, Sisi, Zhuang, Yongxian, Liu, Duan, Lu, Shijia W., Kalari, Krishna R., Visscher, Daniel W., Copland, John A., McLaughlin, Sarah A., Moreno-Aspitia, Alvaro, Gray, Donald W. Northfel Richard J., Lou, Zhenkun, Suman, Vera J., Weinshilboum, Richard, Boughey, Judy C., Goetz, Matthew P., and Wang, Liewei

Subjects
Epigenetic inheritance -- Health aspects, Triple negative breast cancer -- Drug therapy -- Prognosis, Methyltransferases -- Physiological aspects -- Health aspects, Decitabine -- Dosage and administration, Health care industry
Abstract

Triple-negative breast cancer (TNBC) is a heterogeneous disease with poor prognosis that lacks targeted therapies, especially in patients with chemotherapy-resistant disease. Since DNA methylation-induced silencing of tumor suppressors is common in cancer, reversal of promoter DNA hypermethylation by 5-aza-2'-deoxycytidine (decitabine), an FDA-approved DNA methyltransferase (DNMT) inhibitor, has proven effective in treating hematological neoplasms. However, its antitumor effect varies in solid tumors, stressing the importance of identifying biomarkers predictive of therapeutic response. Here, we focused on the identification of biomarkers to select decitabine-sensitive TNBC through increasing our understanding of the mechanism of decitabine action. We showed that protein levels of DNMTs correlated with response to decitabine in patient-derived xenograft (PDX) organoids originating from chemotherapy-sensitive and -resistant TNBCs, suggesting DNMT levels as potential biomarkers of response. Furthermore, all 3 methytransferases, DNMT1, DNMT3A, and DNMT3B, were degraded following low-concentration, long-term decitabine treatment both in vitro and in vivo. The DNMT proteins could be ubiquitinated by the E3 ligase, TNF receptor-associated factor 6 (TRAF6), leading to lysosome-dependent protein degradation. Depletion of TRAF6 blocked decitabine-induced DNMT degradation, conferring resistance to decitabine. Our study suggests a potential mechanism of regulating DNMT protein degradation and DNMT levels as response biomarkers for DNMT inhibitors in TNBCs., Introduction Breast cancer is the second leading cause of cancer death in women, with 40,610 women predicted to die from breast cancer in 2017 (1). Triple-negative breast cancer (TNBC), characterized [...]

Published
2018
Full Text
View/download PDF

27. FOXA1 overexpression suppresses interferon signaling and immune response in cancer

Author

He, Yundong, Wang, Liguo, Wei, Ting, Xiao, Yu-Tian, Sheng, Haoyue, Su, Hengchuan, Hollern, Daniel P., Zhang, Xiaoling, Ma, Jian, Wen, Simeng, Xie, Hongyan, Yan, Yuqian, Pan, Yunqian, Hou, Xiaonan, Tang, Xiaojia, Suman, Vera J., Carter, Jodi M., Weinshilboum, Richard, Wang, Liewei, Kalari, Krishna R., Weroha, Saravut J., Bryce, Alan H., Boughey, Judy C., Dong, Haidong, Perou, Charles M., Ye, Dingwei, Goetz, Matthew P., Ren, Shancheng, and Huang, Haojie

Subjects
Interferon -- Genetic aspects -- Health aspects, Oncology, Experimental, Gene expression -- Research, Prostate cancer -- Genetic aspects -- Development and progression, Immune response -- Genetic aspects -- Health aspects, Cellular signal transduction -- Research, Breast cancer -- Genetic aspects -- Development and progression, Cancer -- Research, Health care industry
Abstract

Androgen receptor-positive prostate cancer (PCa) and estrogen receptor-positive luminal breast cancer (BCa) are generally less responsive to immunotherapy compared with certain tumor types such as melanoma. However, the underlying mechanisms are not fully elucidated. In this study, we found that FOXA1 overexpression inversely correlated with interferon (IFN) signature and antigen presentation gene expression in PCa and BCa patients. FOXA1 bound the STAT2 DNA- binding domain and suppressed STAT2 DNA-binding activity, IFN signaling gene expression, and cancer immune response independently of the transactivation activity of FOXA1 and its mutations detected in PCa and BCa. Increased FOXA1 expression promoted cancer immuno- and chemotherapy resistance in mice and PCa and BCa patients. These findings were also validated in bladder cancer expressing high levels of FOXA1. FOXA1 overexpression could be a prognostic factor to predict therapy resistance and a viable target to sensitize luminal PCa, BCa, and bladder cancer to immuno- and chemotherapy., Introduction Patients with certain cancer types such as melanoma and non-small cell lung cancer have significantly benefited from immunotherapies such as immune checkpoint inhibitors (ICIs) (1). However, ICIs including the [...]

Published
2021
Full Text
View/download PDF

36. Supplementary Data Clean from Anastrozole has an Association between Degree of Estrogen Suppression and Outcomes in Early Breast Cancer and is a Ligand for Estrogen Receptor α

Author

Ingle, James N., primary, Cairns, Junmei, primary, Suman, Vera J., primary, Shepherd, Lois E., primary, Fasching, Peter A., primary, Hoskin, Tanya L., primary, Singh, Ravinder J., primary, Desta, Zeruesenay, primary, Kalari, Krishna R., primary, Ellis, Matthew J., primary, Goss, Paul E., primary, Chen, Bingshu E., primary, Volz, Bernhard, primary, Barman, Poulami, primary, Carlson, Erin E., primary, Haddad, Tufia, primary, Goetz, Matthew P., primary, Goodnature, Barbara, primary, Cuellar, Matthew E., primary, Walters, Michael A., primary, Correia, Cristina, primary, Kaufmann, Scott H., primary, Weinshilboum, Richard M., primary, and Wang, Liewei, primary

Published
2023
Full Text
View/download PDF

37. Supplementary Tables 1-4, Figures 1-2 from Functional Genetic Polymorphisms in the Aromatase Gene CYP19 Vary the Response of Breast Cancer Patients to Neoadjuvant Therapy with Aromatase Inhibitors

Author

Wang, Liewei, primary, Ellsworth, Katarzyna A., primary, Moon, Irene, primary, Pelleymounter, Linda L., primary, Eckloff, Bruce W., primary, Martin, Yvette N., primary, Fridley, Brooke L., primary, Jenkins, Gregory D., primary, Batzler, Anthony, primary, Suman, Vera J., primary, Ravi, Saranya, primary, Dixon, J. Michael, primary, Miller, William R., primary, Wieben, Eric D., primary, Buzdar, Aman, primary, Weinshilboum, Richard M., primary, and Ingle, James N., primary

Published
2023
Full Text
View/download PDF

38. Data from Functional Genetic Polymorphisms in the Aromatase Gene CYP19 Vary the Response of Breast Cancer Patients to Neoadjuvant Therapy with Aromatase Inhibitors

Author

Wang, Liewei, primary, Ellsworth, Katarzyna A., primary, Moon, Irene, primary, Pelleymounter, Linda L., primary, Eckloff, Bruce W., primary, Martin, Yvette N., primary, Fridley, Brooke L., primary, Jenkins, Gregory D., primary, Batzler, Anthony, primary, Suman, Vera J., primary, Ravi, Saranya, primary, Dixon, J. Michael, primary, Miller, William R., primary, Wieben, Eric D., primary, Buzdar, Aman, primary, Weinshilboum, Richard M., primary, and Ingle, James N., primary

Published
2023
Full Text
View/download PDF

41. Training High-Volume Melanoma Surgeons to Perform a Novel Minimally Invasive Inguinal Lymphadenectomy: Report of a Prospective Multi-Institutional Trial

Author

Jakub, James W., Terando, Alicia M., Sarnaik, Amod, Ariyan, Charlotte E., Faries, Mark B., Zani, Sabino, Jr., Neuman, Heather B., Wasif, Nabil, Farma, Jeffrey M., Averbook, Bruce J., Bilimoria, Karl Y., Allred, Jacob B. (Jake), Suman, Vera J., Grotz, Travis E., Zendejas, Benjamin, Wayne, Jeffrey D., and Tyler, Douglas S.

Published
2016
Full Text
View/download PDF

42. Additional file 1 of Integration of multiomics data shows down regulation of mismatch repair and tubulin pathways in triple-negative chemotherapy-resistant breast tumors

Author

Tang, Xiaojia, Thompson, Kevin J., Kalari, Krishna R., Sinnwell, Jason P., Suman, Vera J., Vedell, Peter T., McLaughlin, Sarah A., Northfelt, Donald W., Aspitia, Alvaro Moreno, Gray, Richard J., Carter, Jodi M., Weinshilboum, Richard, Wang, Liewei, Boughey, Judy C., and Goetz, Matthew P.

Abstract

Additional file 1. Supplementary figures.

Published
2023
Full Text
View/download PDF

44. Integration of multi-omics data shows downregulation of mismatch repair, purin, and tubulin pathways in triple-negative chemotherapy-resistant breast tumors

Author

Tang, Xiaojia, primary, Thompson, Kevin J., additional, Kalari, Krishna R., additional, Sinnwell, Jason P., additional, Suman, Vera J., additional, Vedell, Peter T., additional, McLaughlin, Sarah A., additional, Northfelt, Donald W., additional, Aspitia, Alvaro Moreno, additional, Gray, Richard J., additional, Carter, Jodi M., additional, Weinshilboum, Richard, additional, Wang, Liewei, additional, Boughey, Judy C., additional, and Goetz, Matthew P., additional

Published
2022
Full Text
View/download PDF

47. Evaluation of Alisertib Alone or Combined With Fulvestrant in Patients With Endocrine-Resistant Advanced Breast Cancer: The Phase 2 TBCRC041 Randomized Clinical Trial.

Author

Haddad, Tufia C., Suman, Vera J., D'Assoro, Antonino B., Carter, Jodi M., Giridhar, Karthik V., McMenomy, Brendan P., Santo, Katelyn, Mayer, Erica L., Karuturi, Meghan S., Morikawa, Aki, Marcom, P. Kelly, Isaacs, Claudine J., Oh, Sun Young, Clark, Amy S., Mayer, Ingrid A., Keyomarsi, Khandan, Hobday, Timothy J., Peethambaram, Prema P., O'Sullivan, Ciara C., and Leon-Ferre, Roberto A.

Published
2023
Full Text
View/download PDF

48. Fluorouracil, epirubicin, and cyclophosphamide (FEC-75) followed by paclitaxel plus trastuzumab versus paclitaxel plus trastuzumab followed by FEC-75 plus trastuzumab as neoadjuvant treatment for patients with HER2-positive breast cancer (Z1041): a randomised, controlled, phase 3 trial

Author

Buzdar, Aman U, Suman, Vera J, Meric-Bernstam, Funda, Leitch, A Marilyn, Ellis, Matthew J, Boughey, Judy C, Unzeitig, Gary, Royce, Melanie, McCall, Linda M, Ewer, Michael S, and Hunt, Kelly K

Published
2013
Full Text
View/download PDF

49. Establishing and characterizing patient-derived xenografts using pre-chemotherapy percutaneous biopsy and post-chemotherapy surgical samples from a prospective neoadjuvant breast cancer study

Author

Yu, Jia, Qin, Bo, Moyer, Ann M., Sinnwell, Jason P., Thompson, Kevin J., Copland, III, John A., Marlow, Laura A., Miller, James L., Yin, Ping, Gao, Bowen, Minter-Dykhouse, Katherine, Tang, Xiaojia, McLaughlin, Sarah A., Moreno-Aspitia, Alvaro, Schweitzer, Anthony, Lu, Yan, Hubbard, Jason, Northfelt, Donald W., Gray, Richard J., Hunt, Katie, Conners, Amy L., Suman, Vera J., Kalari, Krishna R., Ingle, James N., Lou, Zhenkun, Visscher, Daniel W., Weinshilboum, Richard, Boughey, Judy C., Goetz, Matthew P., and Wang, Liewei

Published
2017
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results